Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Emerging SARS-CoV-2 variants raise concerns on immune evasion. Here, the authors evaluate the neutralization efficiency of COVID-19 mRNA vaccinee sera against representative viruses of 13 WHO-designated SARS-CoV-2 variants of concern/interest.

Bibliographic Details
Main Authors:	Li Wang, Markus H. Kainulainen, Nannan Jiang, Han Di, Gaston Bonenfant, Lisa Mills, Michael Currier, Punya Shrivastava-Ranjan, Brenda M. Calderon, Mili Sheth, Brian R. Mann, Jaber Hossain, Xudong Lin, Sandra Lester, Elizabeth A. Pusch, Joyce Jones, Dan Cui, Payel Chatterjee, M. Harley Jenks, Esther K. Morantz, Gloria P. Larson, Masato Hatta, Jennifer L. Harcourt, Azaibi Tamin, Yan Li, Ying Tao, Kun Zhao, Kristine Lacek, Ashley Burroughs, Wei Wang, Malania Wilson, Terianne Wong, So Hee Park, Suxiang Tong, John R. Barnes, Mark W. Tenforde, Wesley H. Self, Nathan I. Shapiro, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, David N. Hager, Manish Patel, Alison L. Halpin, Laura K. McMullan, Justin S. Lee, Hongjie Xia, Xuping Xie, Pei-Yong Shi, C. Todd Davis, Christina F. Spiropoulou, Natalie J. Thornburg, M. Steven Oberste, Vivien G. Dugan, SSEV Bioinformatics Working Group, David E. Wentworth, Bin Zhou
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-07-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-022-31929-6

Internet

https://doi.org/10.1038/s41467-022-31929-6